-
1دورية أكاديمية
المؤلفون: Meier, Juris J.1 juris.meier@rub.de, Schenker, Nina1, Kahle, Melanie1, Schliess, Freimut2, Kapitza, Christoph2, Menge, Björn A.1
المصدر: Diabetes, Obesity & Metabolism. Nov2017, Vol. 19 Issue 11, p1625-1629. 5p.
مصطلحات موضوعية: *TYPE 2 diabetes treatment, *INSULIN therapy, *GLUCAGON-like peptide-1 agonists, *PANCREATIC beta cells, *COMBINATION drug therapy, *PHYSIOLOGY, *THERAPEUTICS
-
2دورية أكاديمية
المصدر: Diabetes, Obesity & Metabolism; Feb2017, Vol. 19 Issue 2, p216-227, 12p
مصطلحات موضوعية: INSULIN therapy, TYPE 2 diabetes treatment, GLUCAGON-like peptide-1 agonists, LIPOPROTEINS, META-analysis
-
3دورية أكاديمية
المؤلفون: Gitt, Anselm K., Halle, Martin, Hanefeld, Markolf, Kellerer, Monika, Marx, Nikolaus, Meier, Juris J., Schumm-Draeger, Petra-Maria, Bramlage, Peter, Tschöpe, Diethelm
المصدر: European Journal of Heart Failure; Dec2012, Vol. 14 Issue 12, p1389-1400, 12p
مصطلحات موضوعية: HYPOGLYCEMIC agents, TYPE 2 diabetes treatment, HEART failure patients, RANDOMIZED controlled trials, THIAZOLIDINEDIONES, TARGETED drug delivery
-
4دورية أكاديمية
المؤلفون: PENNARTZ, CHRISTIAN, SCHENKER, NINA, MENGE, BJORN A., SCHMIDT, WOLFGANG E., NAUCK, MICHAEL A., MEIER, JURIS J.
المصدر: Diabetes Care; Sep2011, Vol. 34 Issue 9, p2048-2053, 6p, 1 Chart, 2 Graphs
مصطلحات موضوعية: INSULIN, TYPE 2 diabetes treatment, PANCREATIC secretions, HYPOGLYCEMIC agents, METFORMIN, LIVER cells
-
5دورية أكاديمية
المؤلفون: NAUCK, MICHAEL A., DEL PRATO, STEFANO, MEIER, JURIS J., DURÁN-GARCÍA, SANTIAGO, ROHWEDDER, KATJA, ELZE, MARTINA, PARIKH, SHAMIK J.
المصدر: Diabetes Care; Sep2011, Vol. 34 Issue 9, p2015-2022, 8p, 1 Chart, 2 Graphs
مصطلحات موضوعية: HYPOGLYCEMIC agents, TREATMENT of diabetes, METFORMIN, TYPE 2 diabetes treatment, WEIGHT gain, PHYSIOLOGY
-
6دورية أكاديمية
المؤلفون: Nauck, Michael A.1 Michael.nauch@rub.de, Meier, Juris J.1 juris.meier@rub.de
المصدر: Nature Reviews Endocrinology. Dec2016, Vol. 12 Issue 12, p689-690. 2p.
مصطلحات موضوعية: *TYPE 2 diabetes treatment, *INSULIN therapy, *INCRETINS, *GLUCAGON-like peptide-1 receptor, *GLYCEMIC index, *HYPOGLYCEMIC agents, *INSULIN, *TYPE 2 diabetes, *GLUCAGON-like peptide 1, *PROTEASE inhibitors